Tevogen Inc. (TVGNW) stock
TVGNWNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as TVGN
$0.09+0.01 (+18.24%)
Close on Oct 30, 2026Market cap $38.42MP/E –Yield –
Tevogen r&d expenses
Research and development expenses are spending on new products and technology.
Tevogen's R&D Expenses for the twelve months ending Jun 30, 2026 was $11.63M, down 3.0% year over year. For fiscal 2025 it was $11.11M, down 64.2% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.11M | -64.2% |
| FY2024 | Dec 31, 2024 | $31.03M | +604.7% |
| FY2023 | Dec 31, 2023 | $4.40M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $3.28M | +21.6% |
| Q1 FY2026 | Mar 31, 2026 | $3.13M | -1.9% |
| Q4 FY2025 | Dec 31, 2025 | $2.11M | -25.8% |
| Q3 FY2025 | Sep 30, 2025 | $3.11M | -4.6% |
| Q2 FY2025 | Jun 30, 2025 | $2.70M | -34.5% |
| Q1 FY2025 | Mar 31, 2025 | $3.20M | -84.6% |
| Q4 FY2024 | Dec 31, 2024 | $2.84M | +212.4% |
| Q3 FY2024 | Sep 30, 2024 | $3.26M | +192.0% |
| Q2 FY2024 | Jun 30, 2024 | $4.12M | +299.9% |
| Q1 FY2024 | Mar 31, 2024 | $20.81M | +1444.8% |
| Q4 FY2023 | Dec 31, 2023 | $908.05K | – |
| Q3 FY2023 | Sep 30, 2023 | $1.12M | – |
| Q2 FY2023 | Jun 30, 2023 | $1.03M | – |
| Q1 FY2023 | Mar 31, 2023 | $1.35M | – |